NCT02296372View on ClinicalTrials.gov

Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Ill Patients

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

June 30, 2016

Conditions
Glucose Metabolism DisordersDiabetic Blood Glucose MonitoringCritical Illness
Interventions
DEVICE

Continuous glucose monitoring

"Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.~In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems."

Trial Locations (1)

13353

Charite University, Berlin, Germany, Berlin

All Listed Sponsors
lead

Charite University, Berlin, Germany

OTHER

NCT02296372 - Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Ill Patients | Biotech Hunter | Biotech Hunter